Celldex Therapeutics, Inc.
- Last sale
- Nov 12, 2026 · -5.46%
- Market cap
- $2.24B
- 78.55M shares
- Filings
- 1,030
Q3 2026−78.0% FY25 yoy
Q3 2026N/M FY25 yoy
Q3 2026N/M FY25 yoy
Q3 2026derivedN/M FY25 yoy
Q3 2026N/M FY25 yoy
Q3 2026+1.8% FY25 yoy
- $2.24B
- —
- 14172.9×
- 3.4×
- -11.60%
- —
Twelve months to Sep 30, 2026 · derived
Price
Nov 12, 2026 · IEX last sale
IEX last saleClose of record
Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.
Financials
Revenue
| Period | Ended | Value | Kind | Source trail |
|---|---|---|---|---|
| FY 2025 | 2025-12-31 | $1,545,000 | reported | |
| FY 2024 | 2024-12-31 | $7,020,000 | reported | |
| FY 2023 | 2023-12-31 | $6,883,000 | reported | |
| FY 2022 | 2022-12-31 | $2,357,000 | reported | |
| FY 2021 | 2021-12-31 | $4,651,000 | reported | |
| FY 2020 | 2020-12-31 | $7,418,000 | reported | |
| FY 2019 | 2019-12-31 | $3,573,000 | reported | |
| FY 2018 | 2018-12-31 | $9,538,000 | reported | |
| FY 2017 | 2017-12-31 | $12,743,000 | reported | |
| FY 2016 | 2016-12-31 | $6,786,000 | reported | |
| FY 2015 | 2015-12-31 | $5,480,000 | reported | |
| FY 2014 | 2014-12-31 | $3,586,000 | reported |
Segments
Products
LineFY2024ShareChange
Contracts and grants$7.01M100%+6.1%
Product development and licensing agreements$13.00K0.2%−95.3%
Total$7.02M
In vitro & in vivo diagnostic substances
Celldex Therapeutics, Inc. is the 14th largest of the 20 covered companies the SEC files under this code, by revenue. SIC 2835
CompanyRevenueGrowthNet marginMarket cap
NTLAIntellia Therapeutics, Inc.$67.7M16.9%609.9%$1.5BTKNOAlpha Teknova, Inc.$40.5M7.4%42.6%$521.8MICCCImmucell Corp$27.6M4.3%3.8%$89.6MAWHLAspira Women's Health Inc.$9.2M0.4%138.7%$16.3MNNNNAnbio Biotechnology$8.6M5.6%74.1%$554.7MBMRABiomerica Inc$4.5M16.2%84.8%$5.9MIMDXInsight Molecular Diagnostics Inc.$4.1M115.6%1,238.5%$75.3MVNRXVolitionrx Ltd$1.7M40.0%1,352.2%$6.7M
CLDXCelldex Therapeutics, Inc. (this company)$1.5M78.0%16,748.0%$2.2B
Peers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in revenue first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.
Celldex Therapeutics, Inc. · CIK 744218 · Engraved from SEC EDGAR